Preparing for commercialization?
Discuss commercial readiness, launch timing and organizational decisions with PharmaKonsult.
PharmaKonsult Framework
PharmaKonsult Commercial Readiness Framework
Seven pillars for evaluating whether an emerging biotechnology company is prepared to commercialize.
What Is the PharmaKonsult Commercial Readiness Framework?
A biotechnology launch readiness assessment evaluates whether the strategy, organization, capabilities and execution plan are sufficiently developed for commercialization. The PharmaKonsult Commercial Readiness Framework organizes that evaluation into seven pillars used across advisory engagements, board discussions and leadership planning.
The framework is designed for emerging biotechnology companies—particularly those preparing for a first U.S. commercial launch across rare disease, neuroscience and specialty markets.
Seven Pillars of Commercial Readiness
1
Market Reality
Diagnosed population, addressable patients, treatment pathways and competitive dynamics—not prevalence alone.
2
Patient Journey
How patients enter care, where diagnosis is delayed, referral networks and points of abandonment.
3
Evidence
Clinical, economic and real-world evidence required for physician confidence and payer decisions.
4
Access
Reimbursement, specialty pharmacy, patient support and the operational path from prescription to initiation.
5
Organization
Capabilities, structure, hiring sequence and what should be internal versus outsourced.
6
Leadership
Commercial judgment, cross-functional influence, board communication and accountability.
7
Execution
Priorities, owners, milestones, dependencies, metrics and launch governance.
How Leadership Should Use the Framework
The framework should not be treated as a pass-or-fail checklist.
Its purpose is to help leadership identify where uncertainty, capability gaps and execution risk are accumulating while there is still time to act.
A useful readiness discussion should answer:
- Which commercial assumptions remain unvalidated?
- Which capabilities do we need now?
- Which capabilities can wait?
- Where is ownership unclear?
- Which dependencies could delay launch readiness?
- What decisions require board visibility?
- What risks become more expensive if action is delayed?
Readiness should therefore be reassessed as the company advances through development.
Use it alongside the Launch Readiness Assessment, Commercial Readiness Checklist, Commercial Launch Roadmap, Biotech Commercial Strategy and First Commercial Launch.
Who It Is For
Biotechnology CEOs, founders, Chief Commercial Officers, boards, investors and leadership teams preparing for commercialization or evaluating commercial risk before major hiring, financing or partnership decisions.
